company background image
CBAY

CymaBay TherapeuticsNasdaqGS:CBAY Stock Report

Market Cap

US$277.7m

7D

-13.0%

1Y

-54.4%

Updated

03 Dec, 2021

Data

Company Financials +
CBAY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CBAY Stock Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

Price History & Performance

Summary of all time highs, changes and price drops for CymaBay Therapeutics
Historical stock prices
Current Share PriceUS$3.28
52 Week HighUS$7.44
52 Week LowUS$3.18
Beta1.1
1 Month Change-28.70%
3 Month Change-16.75%
1 Year Change-54.44%
3 Year Change-61.86%
5 Year Change81.22%
Change since IPO-63.56%

Recent News & Updates

Dec 03
Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

May 15
We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

CBAYUS PharmaceuticalsUS Market
7D-13.0%-2.3%-2.7%
1Y-54.4%11.6%16.6%

Return vs Industry: CBAY underperformed the US Pharmaceuticals industry which returned 12.4% over the past year.

Return vs Market: CBAY underperformed the US Market which returned 19.4% over the past year.

Price Volatility

Is CBAY's price volatile compared to industry and market?
CBAY volatility
CBAY Average Weekly Movement7.1%
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: CBAY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CBAY's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198841Sujal Shahhttps://www.cymabay.com

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition.

CymaBay Therapeutics Fundamentals Summary

How do CymaBay Therapeutics's earnings and revenue compare to its market cap?
CBAY fundamental statistics
Market CapUS$277.71m
Earnings (TTM)-US$79.21m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CBAY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$38.37m
Gross Profit-US$38.37m
ExpensesUS$40.84m
Earnings-US$79.21m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.94
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio26.7%

How did CBAY perform over the long term?

See historical performance and comparison

Valuation

Is CymaBay Therapeutics undervalued compared to its fair value and its price relative to the market?

3.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CBAY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CBAY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CBAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CBAY is overvalued based on its PB Ratio (3.2x) compared to the US Pharmaceuticals industry average (2.7x).


Future Growth

How is CymaBay Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

19.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CBAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CBAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CBAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CBAY's revenue (85.8% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: CBAY's revenue (85.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CBAY's Return on Equity is forecast to be high in 3 years time


Past Performance

How has CymaBay Therapeutics performed over the past 5 years?

-19.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CBAY is currently unprofitable.

Growing Profit Margin: CBAY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CBAY is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.

Accelerating Growth: Unable to compare CBAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: CBAY has a negative Return on Equity (-90.98%), as it is currently unprofitable.


Financial Health

How is CymaBay Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CBAY's short term assets ($119.6M) exceed its short term liabilities ($11.7M).

Long Term Liabilities: CBAY's short term assets ($119.6M) exceed its long term liabilities ($24.1M).


Debt to Equity History and Analysis

Debt Level: CBAY has more cash than its total debt.

Reducing Debt: CBAY's debt to equity ratio has reduced from 92.8% to 26.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBAY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CBAY has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 22.9% each year.


Dividend

What is CymaBay Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBAY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Sujal Shah (48 yo)

4.75yrs

Tenure

US$2,644,135

Compensation

Mr. Sujal A. Shah serves as Director at Tvardi Therapeutics, Inc. since January 2021. He has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah se...


CEO Compensation Analysis

Compensation vs Market: Sujal's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD1.15M).

Compensation vs Earnings: Sujal's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CBAY's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: CBAY's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.9%.


Top Shareholders

Company Information

CymaBay Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: CymaBay Therapeutics, Inc.
  • Ticker: CBAY
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$277.714m
  • Shares outstanding: 84.67m
  • Website: https://www.cymabay.com

Number of Employees


Location

  • CymaBay Therapeutics, Inc.
  • 7575 Gateway Boulevard
  • Suite 110
  • Newark
  • California
  • 94560
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/03 23:52
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.